Weekly Research Analysts’ Ratings Changes for Atreca (BCEL)

Atreca (NASDAQ: BCEL) recently received a number of ratings updates from brokerages and research firms:

  • 6/25/2020 – Atreca was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/17/2020 – Atreca had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 6/16/2020 – Atreca had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
  • 6/10/2020 – Atreca had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
  • 6/5/2020 – Atreca was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 5/19/2020 – Atreca was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $21.00 price target on the stock. According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets. “
  • 5/18/2020 – Atreca was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets. “
  • 5/15/2020 – Atreca had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
  • 5/13/2020 – Atreca was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets. “

Atreca stock opened at $21.28 on Wednesday. The firm has a 50 day simple moving average of $18.85 and a 200-day simple moving average of $17.65. The stock has a market capitalization of $584.37 million and a PE ratio of -3.74. Atreca has a 12-month low of $9.51 and a 12-month high of $29.35.

Atreca (NASDAQ:BCEL) last issued its earnings results on Thursday, May 14th. The company reported ($0.73) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.73). As a group, equities research analysts forecast that Atreca will post -3.07 earnings per share for the current year.

In related news, insider Tito Serafini sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $16.28, for a total value of $162,800.00. Following the completion of the transaction, the insider now owns 3,655 shares of the company’s stock, valued at approximately $59,503.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Norman Michael Greenberg sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $15.01, for a total transaction of $120,080.00. Following the completion of the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $120,080. The disclosure for this sale can be found here. Insiders have sold 105,200 shares of company stock valued at $1,848,866 over the last 90 days. 9.90% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of BCEL. Ameritas Investment Partners Inc. lifted its position in Atreca by 170.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 1,490 shares of the company’s stock worth $25,000 after buying an additional 940 shares in the last quarter. Legal & General Group Plc lifted its position in Atreca by 105.7% in the 1st quarter. Legal & General Group Plc now owns 2,658 shares of the company’s stock worth $43,000 after buying an additional 1,366 shares in the last quarter. US Bancorp DE purchased a new stake in Atreca in the 1st quarter worth approximately $46,000. Citigroup Inc. lifted its position in Atreca by 673.0% in the 4th quarter. Citigroup Inc. now owns 3,007 shares of the company’s stock worth $47,000 after buying an additional 2,618 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Atreca by 4,968.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,244 shares of the company’s stock worth $50,000 after buying an additional 3,180 shares in the last quarter. 62.14% of the stock is owned by hedge funds and other institutional investors.

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Read More: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply